Trial for blood cancer drug halted before it began
NCT ID NCT04398680
Summary
This early-stage study aimed to understand how a drug for relapsed multiple myeloma is processed by the body in people with different levels of liver function. It planned to compare participants with normal liver function to those with impaired function. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Tucson, Arizona, 85724, United States
-
GSK Investigational Site
Beverly Hills, California, 90211, United States
-
GSK Investigational Site
Plantation, Florida, 33322, United States
-
GSK Investigational Site
Wichita, Kansas, 67214, United States
-
GSK Investigational Site
Baltimore, Maryland, 21201-1595, United States
-
GSK Investigational Site
Monroeville, Pennsylvania, 15146, United States
-
GSK Investigational Site
The Woodlands, Texas, 77380, United States
-
GSK Investigational Site
Milwaukee, Wisconsin, 53233, United States
-
GSK Investigational Site
Athens, 10676, Greece
-
GSK Investigational Site
Daegu, 41944, South Korea
-
GSK Investigational Site
Hwasun, 58128, South Korea
-
GSK Investigational Site
Incheon, 405-760, South Korea
-
GSK Investigational Site
Jeonju, 561-172, South Korea
-
GSK Investigational Site
Pusan, 49241, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Seoul, 120-752, South Korea
-
GSK Investigational Site
Suwon Kyunggi-do, 16499, South Korea
Conditions
Explore the condition pages connected to this study.